AstraZeneca AZN announced that the FDA has expanded the label of its cancer drug Datroway for a second indication — non-small cell lung cancer (NSCLC). The drug has been developed in partnership ...

AstraZeneca secured a fast approval of lung and breast cancer drugs with usually sluggish Japanese regulators, just months after scoring similar approvals in the West. The Japanese Ministry of ...

Immuneering Corporation’s investigational MEK inhibitor aims to outpace cancer while reducing resistance and side effects.

Two impressive studies in lung cancer and another in breast cancer made Sunday a stellar day for AstraZeneca at the ASCO congress. Three of the group’s top cancer drugs were on display – EGFR ...

Companies such as AstraZeneca, Daiichi Sankyo, Pfizer, Merck and GSK are learning from previous setbacks in the ADC space to develop drugs that improve efficacy and reduce side effects.

Artificial intelligence (AI) transforms oncology by enhancing decision-making, improving patient care, and streamlining ...

The global oncology market, including breakthrough treatments, is experiencing substantial growth, with revenues projected to reach hundreds of billions of dollars in the coming years. Several factors ...

Manufacturing companies are particularly attentive to drugs designated as breakthrough therapies due to the accelerated market access and higher returns on investment. Breakthrough therapy drugs often ...

According to the Lung Cancer Research Foundation, an estimated 226,650 people will be diagnosed with lung cancer in 2025 in the U.S. Around 124,730 Americans die from lung cancer each year.

It started a business to give hospitals better access to specialty drugs — for conditions like cancer, H.I.V. and autoimmune diseases — which are major drivers of 340B’s growth.